Approximately 1.6 million adults in the United Kingdom are currently using prescription weight-loss medications such as Wegovy and Mounjaro to manage obesity. While these drugs have been beneficial for many patients, concerns are mounting over the safety of purchasing them through online pharmacies, which now supply the majority of these medications. The National Health Service (NHS) typically restricts access to these drugs to patients with specific medical conditions, leading others to seek out pills from less regulated sources.

Recent investigations have highlighted significant shortcomings in the vetting procedures employed by many online providers. Nearly two-thirds of these pharmacies accepted potentially manipulated identification, including AI-enhanced photos that altered the appearance of an investigator to resemble someone obese. This lax verification raises the possibility that vulnerable individuals, including those with eating disorders, may obtain these medications without adequate medical oversight. Such access is particularly concerning given experts' warnings that weight-loss drugs can pose serious health risks to underweight individuals or those with eating disorders, and require precise dosage control to be used safely.

Furthermore, age verification safeguards prove insufficient, with some vendors allowing under-18s to falsify their ages easily. Questionnaires intended to uncover prior histories of eating disorders are similarly ineffective if applicants choose to provide inaccurate information. In some cases, this cavalier approach to dispensing potent medications may not only undermine public health efforts but could place lives at risk.

The General Pharmaceutical Council has expressed concern about these findings and indicated it will consider whether additional regulatory measures are needed to ensure patient safety. Advocates argue that stronger safeguards and more rigorous checks must be implemented to prevent misuse and protect vulnerable populations.

This issue comes amid the recent introduction of a tablet form of Wegovy’s weight-loss drug, expanding accessibility but also potentially increasing risks associated with self-medication outside of clinical supervision. Regulators and healthcare professionals stress the importance of carefully controlling distribution channels to balance the benefits of these treatments against their potential harms.